https://www.selleckchem.com/pr....oducts/tubastatin-a.
Eligible Black participants were significantly less likely (p .001) to enroll (102, 11%) than trial-eligible White participants (185, 15%). The enrollment rate of BIPOC patients varied by site. The inclusion and prioritization of clinical practices that care for more BIPOC patients contributed to a higher enrollment rate into the trial. Specific efforts to reach BIPOC clinic attendees and prioritize their enrollment had lower yield. Best practices to optimize the enrollment of BIPOC participants into trials that examined comple
Like
Comment
Share
